A $50 Billion Slush Fund Won't Save Rural Hospitals
What resulted was something of a slush fund. The 'rural hospital transformation program' allocates $50 billion toward state grants. Its requirements to participate are broad, to say the least. Half the funds will be given to states that submit a plan to 'transform' rural health care. The rest will be disbursed at the administration's discretion. Perplexingly, there's no requirement that grants actually go to rural hospitals.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 minutes ago
- Yahoo
The sober-curious generation? This map shows where Gen Z is reshaping U.S. drinking habits.
Gen Z is the sober-curious generation. Between 2011 and 2023, the number of adults aged 18 to 24 who drank alcohol dropped by 8 percentage points, according to survey data from the Centers for Disease Control and Prevention. Consumption among 25- to 34-year-olds has also fallen 5 percentage points over the past decade, making young adults the driving force behind America's diminishing alcohol consumption. Gen Z is driving the shift away from drinking. Even young people who do drink do so less frequently than previous generations. Nearly two-thirds of 18- to 34-year-olds say one to two drinks a day is bad for their health, reflecting changing attitudes toward drinking. These days, drinking less doesn't mean sacrificing a social life, though. Bars and liquor stores are catering to a growing demand for mocktails and zero-proof alcohol. Data from Eventbrite shows a 92% rise in sober-curious events across the country over the past year. These include everything from morning dance parties (20% rise) to DJ'd events with coffee instead of alcohol (478% rise). Advertisement Yahoo used data from Behavioral Risk Factor Surveillance System to examine the evolving drinking culture among young adults in the U.S. The map data is based on surveys conducted between 2011-2012 and 2022-2023.
Yahoo
2 minutes ago
- Yahoo
CVS unit must pay $290 million in drug whistleblower lawsuit, judge rules
A federal judge ordered CVS Health's pharmacy benefit manager unit to pay $289.9 million in damages and penalties after it overcharged Medicare for prescription drugs. In a Tuesday decision, Chief Judge Mitchell Goldberg in Philadelphia federal court tripled to $285 million the damages he had ordered CVS Caremark to pay in June, citing the federal False Claims Act. He added a $4.87 million civil fine. Goldberg rejected CVS' request to pay less, saying that while CVS Caremark was liable for only two years of overbilling, evidence at trial "made clear that the fraud was financially motivated, not the result of some innocent or mistaken belief." CVS, based in Woonsocket, said on Wednesday it plans to appeal. Last month, a Manhattan federal judge ordered CVS' Omnicare unit to pay $948.8 million in a separate whistleblower lawsuit alleging fraudulent billing. CVS plans to appeal that judgment. Goldberg presided in March over a non-jury trial in the whistleblower case brought by Sarah Behnke, a former head actuary for Medicare Part D at Aetna. She accused CVS Caremark of having caused health insurers such as Aetna to submit inflated claims since 2010 to the Centers for Medicare and Medicaid Services (CMS), while pharmacies such as Rite Aid and Walgreens WBA.O were paid less. CVS argued that the original $95 million in damages was substantial, and punitive damages should be limited to $95 million. But the judge said CVS Caremark's fraud not only financially harmed the government, but diminished public confidence in it. "CMS relies on companies like Caremark to truthfully and accurately report Part D drug prices," he wrote. "Caremark's conduct broke CMS's trust, and as a result, the public's trust in CMS." Behnke sued in 2014. CVS bought Aetna four years later. The False Claims Act lets whistleblowers sue on behalf of the government and share in recoveries, typically 15% to 30%. This article originally appeared on The Providence Journal: Judge: CVS Caremark overcharged Medicare for prescription drugs Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Washington Post
5 minutes ago
- Washington Post
‘Ozempic For All' is starting to make economic sense
Gary Winslett is an associate professor at Middlebury College in Vermont. By now, you've probably heard about the weight-loss benefits of GLP-1 drugs like Ozempic (semaglutide) and Mounjaro (tirzepatide), but scientists are still discovering that they have all kinds of other benefits too: They help prevent strokes and heart attacks, fight kidney disease and Parkinson's, curb addiction, and lower risks for several particularly nasty cancers.
